When Will Circulating Tumor DNA Be Ready for Prime Time in Lymphoma?

H&O What are the potential uses of circulating tumor DNA (ctDNA) in lymphoma? MR The most impactful potential uses of ctDNA would be to improve outcomes […]

Use of Menin Inhibitors for Acute Leukemia

H&O What is the mechanism of action of menin inhibitors? GI Menin inhibitors are a new class of drugs for patients with acute leukemia that work […]

What Is the Role of Asciminib in Chronic Myeloid Leukemia?

H&O What is the mechanism of action of asciminib? JC Asciminib (Scemblix, Novartis) is a tyrosine kinase inhibitor (TKI) that has a unique mechanism of action […]

Using Imetelstat for Lower-Risk Myelodysplastic Syndromes

H&O Who is eligible for treatment with imetelstat? VS Imetelstat (Rytelo, Geron) is approved for use in adults with myelodysplastic syndromes (MDS) of low to intermediate-1 […]

Is There a Universal Standard of Care for Frontline Therapy in Multiple Myeloma?

H&O What is the most common regimen for frontline treatment in multiple myeloma? SL The standard regimen in the United States for fit patients with multiple […]

Is Doublet Therapy Becoming a Standard of Care in Myelofibrosis?

H&O When is doublet therapy used in myelofibrosis? RR Single-agent Janus kinase (JAK) inhibitors are the mainstay of therapy in myelofibrosis, and a total of 4 […]

Development of Chimeric Antigen Receptor Natural Killer–Cell Therapy

H&O What is chimeric antigen receptor natural killer (CAR NK)-cell therapy? KR Most people are familiar with the groundbreaking work done with CAR T-cell therapy, which […]

Is There a New Standard-of-Care Therapy for Advanced Hodgkin Lymphoma?

H&O What has been the traditional treatment for patients with advanced Hodgkin lymphoma? AH The traditional treatment for patients with stage III or IV Hodgkin lymphoma […]

Chimeric Antigen Receptor T-Cell Therapy for T-Cell Acute Lymphocytic Leukemia

H&O What are the limitations of current treatments for T-cell acute lymphocytic leukemia (ALL)? IA Although with modern ALL regimens the outcomes for patients with newly […]

Should Ponatinib Be the Standard-of-Care Tyrosine Kinase Inhibitor in Ph+ ALL?

H&O How common is Philadelphia chromosome–positive (Ph+) acute lymphocytic leukemia (ALL)? EJ The Ph+ form of ALL is characterized by the presence of the t(9;22) translocation […]

Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?

H&O What is luspatercept, and how does it work for patients who have anemia associated with transfusion-dependent low-risk myelodysplastic syndromes (LR-MDS)? GCM Luspatercept (Reblozyl, Celgene/BMS) is […]

Can We Cure Ph+ ALL Without Chemotherapy or Transplant?

H&O What is Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), and how is it typically managed? RF Ph+ ALL is the most frequent genetic ALL subgroup […]

Pilot Data on Axicabtagene Ciloleucel for CNS Lymphoma

H&O Could you describe the impetus for and design of your pilot study on axicabtagene ciloleucel for CNS lymphoma? CJ When lymphomas that involve the central […]

The Development of Menin Inhibitors in AML and ALL

H&O What are menin inhibitors, and how do they function in the context of acute myeloid leukemia/acute lymphoblastic leukemia? GI Menin inhibitors are a new form […]

Epcoritamab, a Promising Therapy for Richter Syndrome?

H&O What defines Richter syndrome? AK Richter syndrome (RS), also known as Richter transformation, refers to the development of an aggressive lymphoma in the setting of […]

The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma

H&O What is glofitamab, and how does it work for patients with relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? LF Glofitamab (Columvi, Genentech) is […]

Update on the CAPTIVATE Trial of Ibrutinib Plus Venetoclax

H&O Could you describe the impetus for and design of the CAPTIVATE trial? TS The large, multicenter, phase 2 CAPTIVATE trial focused on patients with chronic […]

Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma

H&O What is mosunetuzumab (Lunsumio, Genentech) and how does it work? LEB Mosunetuzumab is a bispecific antibody-based T-cell engager with 2 binding sites. Unlike conventional monoclonal […]

Is Blinatumomab Now Standard of Care Consolidation for Patients With ALL?

H&O What is blinatumomab and how does it work in treating acute lymphocytic leukemia (ALL)? SL Blinatumomab (Blincyto, Amgen), which is classified as a bispecific antibody, […]

Quizartinib, the Next FLT3 Inhibitor

H&O What are FMS-like tyrosine kinase 3 (FLT3) inhibitors, and how have they affected the treatment of patients with acute myeloid leukemia (AML)? JC FLT3 mutations […]